Managing COPD in the Era of COVID-19

Target Audience

The educational design of this activity addresses the needs of primary care and pulmonology clinicians, including physicians, nurse practitioners, and physician assistants, who manage patients with chronic obstructive pulmonary disease (COPD).

Statement of Need/Program Overview

Initially, the relationship of COPD and COVID-19 in terms of disease severity and adverse outcomes was a moving target due to the sparsity of patient-level data. We now know that the magnitude of COVID-19 risk—contracting COVID or having poor outcomes—attributed solely to COPD is less than anticipated; potentially reflecting the effects of maintenance therapies and the protective behavioral measures implemented to shield vulnerable populations. In this module, our expert faculty will review recommendations for COPD assessment and management during the era of COVID-19 as well as discuss how to treat and mitigate risk of COVID-19 infection in patients with COPD.

Educational Objectives

After completing this activity, the participant should be better able to:

• Implement recent guidelines on COPD management, including Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations, in day-to-day clinical practice
• Tailor maintenance treatment regimens for COPD to reflect symptom severity, exacerbation risk, comorbidities, and patient needs/preferences

Faculty

Fernando J. Martinez, MD, MS
Chief, Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York - Presbyterian Hospital/Weill Cornell Medical Center
New York, New York

Sally K. Miller, PhD, CRNP, FNP-BC, AGACN-BC, AGPCNP-BC, PMHNP-BC, FAANP
Clinical Professor
Drexel University
College of Nursing and Health Professions
Department of Advanced Practice Nursing
Philadelphia, Pennsylvania

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global and Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

The planners and managers have the following relevant financial relationships with ineligible companies:

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.